Augmented antibody-dependent cell-mediated cytotoxicity following sensitization or nonspecific stimulation of human effector cells

J M ConnollyJ R Wunderlich


Human peripheral blood leukocytes were stimulated in vitro with mitogens (poke-weed mitogen, concanavalin A, and phytohemagglutinin) or allogeneic cells. Each form of stimulation augmented the cytotoxic effector cell activity of lymphoid cells in a 4-hr test for antibody-dependent cell-mediated cytotoxicity. This augmented activity did not involve release of detectable nonspecific toxins, nor did it require the presence of mitogen during the cytotoxicity test. Stimulated attacking cells appeared more cytotoxic either because of a more potent cytotoxic mechanism per individual cytotoxic cell or because of an increased percentage of cytotoxic cells.


Apr 1, 1987·Veterinary Immunology and Immunopathology·M Campos, C R Rossi
Jan 1, 1976·Scandinavian Journal of Immunology·B RubinM Hoier-Madsen
Jun 1, 1976·Scandinavian Journal of Immunology·W P ZeijlemakerV P Eijsvoogel
Mar 15, 1980·International Journal of Cancer. Journal International Du Cancer·G R ShellamH J Dawkins
Jul 1, 1990·Journal of Psychoactive Drugs·B SpuntT Miller
Apr 1, 1995·Journal of Psychoactive Drugs·B SpuntH J Liberty

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.